# **Special Issue**

# Nano-Based Technology for Glioblastoma

## Message from the Guest Editors

Nano-based technology offers promising avenues for treating glioblastoma, the most common and deadliest form of primary brain cancer in adults. Innovative approaches utilizing nanoparticles to deliver therapeutic agents directly to tumor cells have been successfully designed to enhance drug efficacy while minimizing offtarget effects. Nanoparticles can not only penetrate the blood-brain barrier, allowing for targeted drug delivery to tumor cells, but can also be engineered to release drugs in response to specific stimuli within the tumor microenvironment. This Special Issue aims to include original research articles and reviews within, but not limited to, the following research areas: design and development of nanoparticles that specifically target alioblastoma cells: strategies to enhance the ability of nanoparticles to penetrate the blood-brain barrier; engineering stimuli-responsive nanoparticles or immunomodulatory nanoparticles; nano-delivery platforms for combination therapies; imaging, diagnosis, and theranostics with nano-based systems, among others. We look forward to receiving your contributions.

### **Guest Editors**

### Dr. Maria João Ramalho

1. LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal 2. ALiCE—Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

### Dr. Joana Peixoto

1. i3S - i3S—Institute for Research and Innovation in Health, University of Porto, 4200-135 Porto, Portugal

2. LEPABE—Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, 4200-465 Porto, Portugal

## Deadline for manuscript submissions

20 April 2026



# **Pharmaceutics**

an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/202645

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

#### Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

